LUXE, GTWO, GELV, BMGP, WWPW, LJPC, SNSS, JYHW, BTIM, RMDM, PMDP OTCPicks.com Daily Market Movers Digest Midday Report for Tuesday, December 8th
Our Stocks to Watch
today include Lux Energy Corp. (OTCBB: LUXE), Gen2Media Corp. (OTCBB: GTWO),
Green Energy Live Inc. (OTCBB: GELV), Biomagnetics Diagnostics Corp. (OTC:
BMGP), Wind Works Power Corp. (OTCBB: WWPW), La Jolla Pharmaceutical Co.
(Nasdaq: LJPC), Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS), JayHawk Energy
Inc. (OTCBB: JYHW), BioTime Inc. (NYSE Amex: BTIM), RMD Entertainment Group
(OTC: RMDM) and Plateau Mineral Development Inc. (OTC: PMDP).
Visit http://www.otcpicks.com/hotpicks.htm
to register for our Daily Market Mover’s Digest Newsletter and Email Stock
Watch Alerts.
LUX ENERGY
CORPORATION (OTCBB: LUXE)
Detailed Quote: http://www.otcpicks.com/quotes/LUXE.php
Company Profile: http://www.otcpicks.com/lux-energy-corp/lux-energy-corp.htm
Lux Energy Corp. is
an oil and gas production and exploration company focusing on developing oil
and gas resources in North America. Further
information and news releases are available at www.luxenergycorp.com.
LUXE News:
December 8 - Lux
Energy Corp Announces Private Funding
Lux Energy Corp.
(OTCBB: LUXE), an oil and gas production and exploration company, announced an
agreement for securing a longer-term private funding source(s) under terms that
allow the Company to proceed with current, potentially significant
opportunities.
Lux Energy will
initially receive approximately $400,000.00 (USD) as the first funding tranche,
which is expected to be advanced over the next several weeks by the private
equity firm under agreement with the Company. The total funding amount may
reach a maximum of three million U.S. dollars.
Lux Energy Corp. will
secure the funds with a promissory note. Subsequently the note will be
converted into common shares issued from the corporate treasury. The rate of
the note conversion will be predicated on a five day average trading value
basis.
Shane Broesky,
President of Lux Energy Corp. comments, "The funds are arriving at a
critical juncture for the Company as we embark on our Woodrush venture with
Dejour Enterprises in Northern British Columbia
and our West Central Alberta entrance into the Barrhead fields. Lux Energy
shareholders should note that the timing and terms of this funding has put the
Company in an enviable position to capitalize on these notable petroleum
opportunities throughout 2010 and beyond."
The necessary
reporting requirements for this funding project will be filed by the corporate
attorney with the regulatory agencies imminently.
GEN2MEDIA CORPORATION
(OTCBB: GTWO)
Detailed Quote: www.otcpicks.com/quotes/GTWO.php
Company Profile: http://www.otcpicks.com/Newsletter/GTWO_102809.html
Gen2Media is a fully
integrated technology, production and marketing company whose proprietary and
patent-pending technology has earned the trust of a growing, globally
diversified customer base, comprised of leading media companies, corporations,
chart-topping artists, entertainment companies, advertising agencies and
national brands such as The Black Eyed Peas, Mary J. Blige, Britney Spears,
Justin Timberlake, Microsoft Xbox LIVE, Coca-Cola Company, Toyota, Clear
Channel, and others.
GTWO News:
December 8 -
Gen2Media President Mary Spio Accepts Invitation to Join USA Today
Panel; Will Advise on Leadership Trends, Panel Includes Dozens from Fortune
1000
Gen2Media Corporation
(OTCBB: GTWO), an innovative full service video technology and production
company, announces Co-Founder and President Mary Spio has accepted an
invitation to join a USA Today panel of CEOs, Presidents, Founders, and
Chairmen. The panel includes over 1000 select executives from various
industries including dozens from the Fortune 1000. Ms. Spio will advise on
leadership trends a few times a year.
Del Jones, Corporate
Management Reporter for USA Today, said he was impressed with Mary Spio’s
career; from a server at McDonalds to a Digital Media Expert consulting on marketing
strategies with the world’s most iconic names and brands. He said that an
executive of her caliber with a client base of national brands like Coca-Cola
and Microsoft definitely adds another level of expertise to the panel.
Mary Spio notes, “I
am truly honored to be part of this exclusive USA Today panel. My team at
Gen2Media is certainly at the cutting edge of the latest marketing trends in
digital media. As the focus continues to shift from traditional to online
presentations, Gen2Media is called upon to offer innovative tools that help our
clients engage and interact with their customers. We offer truly impactful
advertising opportunities and create amazing videos for clients over and over
again.”
GREEN ENERGY LIVE
INCORPORATED (OTCBB: GELV)
Detailed Quote: www.otcpicks.com/quotes/GELV.php
Company Profile: http://www.otcpicks.com/green-energy-live.htm
Green Energy Live
Inc. is engaged in developing sustainable biomass-to-energy conversion
technology to meet a critical need for the nation's $154 billion livestock
industry. The company plans to use its proprietary gasification technology for
the development of highly innovative, on-site manure-to-electricity conversion
systems to enable livestock farmers and ranchers to convert their animal waste
into clean, renewable energy.
GELV News:
December 8 - Skymark
Research Initiates Independent Research Coverage on Green Energy Live
Skymark Research, a
leading provider of small- and micro-cap independent investment research, has
initiated coverage on Green Energy Live (OTCBB: GELV). Skymark Research is
currently offering a complimentary trial subscription. To view the company's
research, visit www.skymarkresearch.com.
December 7 - Green
Energy Live Reports on Ongoing Revenue, Distribution Channel, and Customer
Contacts Provided by New Subsidiary Business
Green Energy Live
Inc. (OTCBB: GELV), a growing clean energy company engaged in developing
sustainable biomass-to-energy conversion solutions for the U.S. livestock
industry, reports that its acquisition of Comanche Livestock Exchange
("Comanche") has significantly enhanced the company's strategic and
financial position. Comanche, which is now a wholly-owned subsidiary of Green
Energy Live, provides ongoing revenue, livestock industry expertise, an
established distribution channel and contacts with potential customers,
improving Green Energy Live's ability to develop and sell manure-to-energy
conversion systems.
Green Energy Live
subsidiary Comanche is a leanly operated, profitable and growing business that
provides ongoing revenue to support company growth and technology development.
Comanche has a proven track record of success as a provider of live animal
auction and livestock hauling services. In business since 1949, Comanche has an
extensive network of livestock industry contacts, existing farm and ranch
customers and deep industry expertise. Comanche's management is contracted to
stay in place for a minimum of two years. Its established sales and management
teams will provide a strategic sales channel for Green Energy Live's
manure-to-energy conversion systems.
Green Energy Live
plans to use its proprietary gasification technology to develop self contained,
small footprint, renewable energy gasification systems to enable livestock
operators to convert animal waste into clean energy. The company is focused on
innovative biowaste conversion technologies that process methane gas from the
manure of cows, pigs, turkeys, chickens and convert it into electricity to
supply the farm's power requirements and generate revenue selling surplus power
back to local utilities.
Karen Clark,
President/CEO of Green Energy Live, commented: "Green Energy Live's
acquisition of Comanche Livestock Exchange is a strategic move that strengthens
our operational and financial foundations and positions us for sustained
growth. Comanche's existing relationships and excellent reputation give us a
firm foothold in the industry as well as an established distribution channel
for our manure-to-energy conversion technology. We look forward to building on
this synergistic relationship for the benefit of shareholders."
BIOMAGNETICS
DIAGNOSTICS CORPORATION (OTC: BMGP)
Detailed Quote: http://www.otcpicks.com/quotes/BMGP.php
Company Profile: http://www.otcpicks.com/biomagnetics-diagnostics/biomagnetics-diagnostics.htm
Biomagnetics
Diagnostics Corporation is an advanced medical device and biotechnology
company. The Company's revolutionary diagnostic systems, which are based on
advanced magnetics, test for any viral or bacterial disease using any body
fluid. The Company's technology allows laboratories to perform far more tests
in the same amount of time it takes to do a single test. The HTS-MTP platform
is designed to detect the actual virus and viral load in body fluids and not
just simply screen for the presence of viral antibodies.
BMGP News:
December 8 - Emerging
Growth Research Issues Updated Report on Biomagnetics Diagnostics Corp.
Emerging Growth
Research, LLP, an independent Wall Street research firm specializing in the
networking and telecommunications markets, has issued an updated report on
Biomagnetics Diagnostics Corp. (OTC: BMGP).
In the report,
analyst Joseph Noel says he believes BMGP shares are “worth four times the
current value.” To learn why, visit:
www.otcpicks.com/Newsletter/BMGP_Report_120809.pdf.
Biomagnetics Further
Strengthens Balance Sheet
Company to accelerate
roll out of integrated optical biosensor technology originally developed at Los
Alamos National Laboratory
Biomagnetics
Diagnostics Corp. (OTC: BMGP) a developer of revolutionary diagnostic systems
and technology for HIV, hepatitis, tuberculosis and malaria detection,
announced that it has moved to further enhance its balance sheet via the
acquisition of additional equity growth capital from several institutional and
private investors. These funds will be used to accelerate the Company's entry
into the market for integrated optical biosensors targeting HIV/AIDS, malaria,
tuberculosis, cholera and other pathogen detection and disease diagnosis.
“The acquisition of
this additional capital allows us increased flexibility to move into our chosen
markets much more quickly. We are already working closely with one of the
leading contract engineering design firms in Silicon
Valley toward the aim of producing our initial production run,”
commented Clayton Hardman, CEO of Biomagnetics Diagnostics. “We will also be
investing in development relating to the recently acquired rights to the patent
for “Quantitative Multiplex Detection of Pathogen Biomarkers,” which will allow
us to develop an integrated optical biosensor product capable of detecting
multiple pathogens from a single blood sample.
After the acquisition
of this equity growth capital, Biomagnetics Diagnostics has only approximately
64 million outstanding shares. Management believes current working capital
levels will be sufficient to bring its current set of products to market.
The Company recently
announced it had finalized a "Patent License Agreement with Los Alamos
National Security." Under the agreement, Biomagnetics will have access to
the Triggered Optical Biosensor and Integrated Optical Biosensor System (IBOS)
technology developed at Los Alamos National Laboratory.
According to the
World Health Organization, some 3.2 billion people, or about half of the
world's population is at risk of malaria transmission in 107 countries and
territories worldwide. While there are between 350 million and 500 million new
cases of malaria each year, there are very few reliable and field deployable
diagnostic tools available. In the case of malaria, early detection
substantially improves treatability and survivability. Field deployable
Integrated Optical Biosensor System (IBOS), such as those Biomagnetics
Diagnostics is planning to soon introduce, hold the promise to significantly
speed the diagnostic testing process and to meaningfully lower costs and
improve lives.
WIND WORKS POWER
CORPORATION (OTCBB: WWPW)
Detailed Quote: http://www.otcpicks.com/quotes/WWPW.php
Company Profile: http://www.otcpicks.com/wind-works-power.htm
Wind Works' mission
is to become a leading developer of wind energy projects in North America and Europe.
WWPW News:
November 30 - Wind
Works Power Corp. Submits Power Contract Applications Totaling 100 MW for 8
Wind Energy Projects Under the New Feed-In Tariff Program in Ontario
Wind Works Power
Corp. (OTCBB: WWPW) (Frankfurt: R5E1)(WKN: AOKE72) announces it has submitted
power contract applications for 8 wind energy projects representing a total of
100 megawatts (MW) under the new Feed-in Tariff program as part of the Ontario
Power Authority initial launch period.
"Wind Works has
now submitted power contracts for 9 wind energy projects totaling 110MW, which
includes the 10MW Clean Breeze project which was submitted earlier"
commented Dr. Ingo Stuckmann, CEO and director of Wind Works. "We look
forward to being awarded power contracts, as our stated objective is to
commence construction on a minimum of 20MW of wind energy projects in Ontario by 2011. With
our recently announced financing, plus the proceeds from the flow-through funds
that we are raising up until the end of the calendar year, we will have sufficient
capital to continue development of our project portfolio resulting in
materially significant value being added to the Company."
Power contract
applications have now been submitted for the following Ontario projects:
1. Grey Highlands
Wind Park:
100% interest in a 10 MW project 25kms south of Georgian Bay, Ontario, Canada;
2. Snowy Ridge Wind Park:
100% interest in a 10 MW project in the vicinity west of the village of Bethany,
Ontario, Canada;
3. Settlers Landing
Wind Park:
50% interest (with an option to increase to 100%) in a 10MW project located
near Pontypool, Ontario, Canada;
4. Skyway 126 Wind
Park: 70% interest in a 10 MW project located in Grey-Highlands Township,
Ontario, Canada on the north east side of the Garafraxa Plateau, the highest
land mass in Ontario;
5. Polar Bear Wind
Park: 50% interest (with an option to increase to 100%) in a 20MW project
located in Ontario, Canada;
6. Pleasant Bay Wind
Park: 50% interest (with an option to increase to 100%) in a 20MW project
located in an area just north of the shores of Lake Ontario that has one of the
best wind regimes in Ontario;
7. Zorra Wind Park: 50% interest (with an option to increase to
100%) in a 10MW project located northwest of Woodstock, Ontario, Canada;
8. Whispering Woods
Wind Park:
50% interest (with an option to increase to 100%) in a 10MW project located
near Millbrook, Ontario, Canada;
and
9. Clean Breeze
Wind Park:
50% interest (with an option to increase to 100%) in a 10MW project located in Ontario, Canada.
The Feed-in Tariff
(FIT) contract program is part of the new Green Energy Act in Ontario and offers a power contract with a
guaranteed rate of C$135.00/MWh over a 20-year term to qualified wind energy
projects. The Ontario Power Authority (OPA) initial launch period deadline for
FIT applications is November 30, 2009. This first launch period is designed for
projects that were being developed under the Renewable Energy Standard Offer
Program (RESOP) and are therefore further advanced. Criteria of earlier
commercial operation dates is one such factor in obtaining priority access to
transmission availability. To be awarded a Power Purchase Agreement (PPA) under
the FIT rules, the application has to be submitted in accordance with strict
regulations which can be accessed in details via the OPA website.
About Zero Emission
People
The vision of Zero
Emission People is to provide the opportunity for anyone to invest early in the
development of renewable wind energy projects. As an example, as little as a
$10,000 investment in a wind park blows away a person's carbon footprint. We
believe in making sound, environmentally conscious investments that are good
for all shareholders, people and our planet.
LA JOLLA
PHARMACEUTICAL COMPANY (NASDAQ: LJPC)
"Up 63.23% in
morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/LJPC.php
La Jolla
Pharmaceutical Company is dedicated to improving and preserving human life by
developing innovative pharmaceutical products. The Company's leading product in
development is Riquent®, which is designed to treat lupus renal disease by
preventing or delaying renal flares. Lupus renal disease is a leading cause of
sickness and death in patients with lupus. The Company has also developed
potential small molecule drug candidates to treat various other autoimmune and
inflammatory conditions.
LJPC News:
December 8 - Emerging
Stock Report Initiates Independent Research Coverage on La Jolla Pharmaceutical
Company
Emerging Stock Report,
a leading provider of sector specific independent investment research, has
initiated coverage on La Jolla Pharmaceutical Company (Nasdaq: LJPC). Emerging
Stock Report is currently offering a complimentary trial subscription to the
investment community. To view the report in its entirety visit
www.emergingstockreport.com.
December 7 - Adamis
Pharmaceuticals Announces Signing of Definitive Merger Agreement
Adamis
Pharmaceuticals Corporation (OTCBB: ADMP), announced that it has entered into a
definitive merger agreement providing for the acquisition of La Jolla
Pharmaceutical Company (Nasdaq: LJPC) by Adamis. The transaction was
unanimously approved by the boards of directors of both companies and is
anticipated to close by the end of the first calendar quarter of 2010 or as
soon thereafter as possible. Completion of the transaction is subject to a
number of customary closing conditions, including the effectiveness of a
registration statement to be filed with the Securities and Exchange Commission
relating to the transaction, and approval of Adamis’ and La
Jolla’s respective stockholders at stockholder meetings following
distribution of a definitive joint proxy statement. After completion of the
merger, the combined company expects to trade under the name “Adamis
Pharmaceuticals Corporation”.
Adamis’ chief
executive officer, Dr. Dennis J. Carlo, will become the chief executive officer
of the combined company. Dr. Carlo is a veteran of the pharmaceutical and
biotechnology industry. He previously served as CEO of publicly-traded Immune
Response Corporation, Vice President of Research and Development and
Therapeutic manufacturing of Hybritech Inc. prior to its acquisition by Eli
Lilly & Co., and Director of Bacterial Vaccines and Immunology at Merck
& Company. Dr. Carlo stated, “This merger is a strategic move to raise
additional capital for the purpose of increasing the marketing and sales
efforts of our Epinephrine Injection USP 1:1000 (0.3mg Pre-Filled Single Dose
Syringe) product that we recently launched. In addition, we believe that La Jolla has over ten thousand stockholders and we look
forward to them joining the Adamis stockholder base.” Based on its most recent
quarterly report filed with the Securities and Exchange Commission, at
September 30, 2009, La Jolla had cash and cash
equivalents of approximately $5.8 million and liabilities of approximately $1.0
million. La Jolla anticipates that there will
be $2.5 million to $3.0 million net cash left in the company at the time of the
merger.
Dr. Deirdre Y. Gillespie,
La Jolla’s CEO, stated, “The merger of La Jolla and Adamis will create a new
specialty pharmaceutical company focused on the development and
commercialization of therapeutic products for a variety of viral diseases,
including hepatitis and influenza. We like the fact that in addition to the
prefilled epinephrine syringe, Adamis has a pipeline including products for
allergic rhinitis, asthma, and chronic obstructive pulmonary disease. We think
Adamis is very unique in that it already has a product on the market and is
expected to be profitable in the near-term.”
At the effective time
of the merger, each outstanding share of Adamis common stock will be converted
into the right to receive one (post-reverse stock split) share of La Jolla common stock. Adamis currently has approximately
46 million outstanding shares of common stock, excluding options, warrants and
convertible securities. If the transaction is approved by the stockholders,
immediately before the closing of the merger La Jolla will implement a reverse
stock split; the precise ratio of the reverse stock split will be determined in
accordance with the terms of the merger agreement and is dependent on La
Jolla’s net cash at closing (reduced by the amount of La Jolla’s liabilities as
of the closing date) and Adamis’ stock price over a period before the closing
date subject to a variable discount (which in no event will yield a stock price
that is less than $0.20 or greater than $1.50).
The percentage
ownership of shares after the merger that will be held by persons who were La
Jolla stockholders and Adamis stockholders, respectively, will depend on many
factors, including without limitation the reverse stock split ratio for the La Jolla shares, the number of outstanding Adamis shares
at the closing date of the merger and other factors. However, Adamis expects
that after the closing of the merger, the persons who were La
Jolla stockholders before the merger could hold approximately 5% -
30% of the outstanding shares of the combined company. Actual ownership
percentages could be higher or lower than these estimates.
The merger agreement
contains customary non-solicitation provisions restricting La
Jolla’s and Adamis’ rights to negotiate or enter into other
acquisition or sale transactions before the closing of the merger, subject to
limited exceptions. The merger agreement also contains a number of customary
representations, warranties and covenants of both parties. The merger agreement
contains certain termination rights for both La Jolla
and Adamis upon the occurrence of certain events, and further provides that
upon termination of the merger agreement under specified circumstances, either
party may be required to pay the other party a termination fee. The merger is
intended to qualify for federal income tax purposes as a tax-free
reorganization under the provisions of Section 368(a) of the U.S. Internal
Revenue Code of 1986, as amended.
ABOUT ADAMIS
PHARMACEUTICALS
Adamis
Pharmaceuticals has two wholly owned subsidiaries, Adamis Laboratories and Adamis
Viral Therapies. Adamis Labs expects to launch a series of niche prescription
products in the allergy and respiratory therapeutic area, beginning with the
Epinephrine Injection USP 1:1000 (0.3mg Pre-Filled Single Dose Syringe)
product. Adamis Viral Therapies is focused on the development of patented,
proprietary vaccine technology that Adamis believes may have the capability of
generating a broad-based immunity for both B Cells (antibody) and T cells (cell
mediated immunity). If successful, Adamis’ technology could lead to the
development of new vaccines against a multitude of viruses, including chronic
hepatitis and all forms of influenza. Shoreline Pacific has acted in an
advisory role to Adamis during this transaction.
SUNESIS
PHARMACEUTICALS INCORPORATED (NASDAQ: SNSS)
"Up 34.02% in
morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SNSS.php
Sunesis is a
biopharmaceutical company focused on the development and commercialization of
new oncology therapeutics for the treatment of solid and hematologic cancers.
Sunesis has built a highly experienced cancer drug development organization
committed to advancing its lead product candidate, voreloxin, in multiple
indications to improve the lives of people with cancer.
SNSS News:
December 7 - Sunesis
Presents Positive Phase 2 Clinical Data of Voreloxin in Acute Myeloid Leukemia
at the American Society of Hematology 2009 Annual Meeting
Conference Call
Scheduled for December 8 at 2:00 PM EST to Discuss ASH Data Presentations
Sunesis
Pharmaceuticals, Inc. (Nasdaq: SNSS) announced positive data from two Phase 2
clinical trials of the Company's lead drug candidate, voreloxin. The results
highlight voreloxin's strong efficacy and safety profile when used as a single
agent or in combination with chemotherapy in patients with difficult to treat
acute myeloid leukemia (AML). The trial results were presented at the 51st
American Society Hematology (ASH) Annual Meeting in New Orleans, LA.
The presentations are available on the Sunesis website at www.sunesis.com.
"These results
provide us with the efficacy and safety data to move voreloxin forward into
pivotal testing," said Steven Ketchum, Ph.D., Senior Vice President of
Research and Development at Sunesis. "Trial results show that the high
rates of remission observed in both trials have translated into durable effects
with meaningful preliminary overall survival results. With an anticipated
median survival of three and a half to six months on currently available
therapies, primary refractory and first relapse AML patients are particularly
in desperate need of more effective treatment options. We look forward to
discussing these data with the FDA in our End-of-Phase 2 meeting scheduled for
the first quarter of 2010."
Phase 1b/2 Clinical
Trial of Voreloxin in Combination with Cytarabine in Relapsed/Refractory
(Abstract No. 645)
In an oral
presentation, Jeffrey Lancet, M.D., Associate Member, Section Chief - Leukemia,
Department of Hematologic Malignancies, at the H. Lee Moffitt Cancer Center
& Research Institute and a clinical trial investigator, presented data from
a Phase 1b/2 clinical trial testing voreloxin in combination with cytarabine, a
widely used chemotherapy, in patients with relapsed or refractory AML. The
trial is designed to evaluate the safety, pharmacokinetics and anti-leukemic
activity of escalating doses of voreloxin when administered in combination with
cytarabine given either as continuous infusion or as a two hour IV infusion. To
date, 66 patients have been treated in the expansion Phase 2 populations of the
trial, which includes primary refractory and first relapse AML patients. Of
these, 64 patients were evaluable for efficacy outcomes.
* Among evaluable
first relapse (n=36) and primary refractory patients (n=28), preliminary median
overall survival is 7.8 months and the remission rate is 31% (complete
remission [CR] 27%, complete remission without full platelet recovery [CRp] 2%
and complete remission with incomplete recovery [CRi] 2%). Historical median
overall survival data in primary refractory and first relapse patients on
currently available chemotherapies range from 3.4 to 5.9 months.
* Voreloxin in
combination with either bolus or continuous infusion cytarabine was generally
well-tolerated. Infection-related toxicities were the most common Grade 3 or
higher non-hematologic adverse events. In addition, Grade 3 or higher oral
mucositis was observed.
* All-cause mortality
among these patients was 1% at 30 days and 8% at 60 days.
* A recommended
pivotal dose-regimen of voreloxin used in combination with cytarabine has been
identified.
"Voreloxin has
induced remissions in difficult to treat relapsed, primary refractory and
relapsed/refractory AML patients," said Dr. Lancet. "Voreloxin used
in combination with cytarabine has demonstrated meaningful anti-leukemic
activity with an acceptable tolerability profile in these difficult-to-treat
patients."
Phase 2 Clinical
Trial of Single Agent Voreloxin in Newly Diagnosed Elderly AML (REVEAL-1 Trial)
(Abstract No. 1037)
In a poster
presentation, investigators presented data from the fully enrolled REVEAL-1
(Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose optimization
trial of single agent voreloxin in previously untreated, elderly AML patients
who are unlikely to benefit from standard induction chemotherapy. 113 AML
patients have been treated in the trial, all of whom had at least one
additional adverse risk factor at enrollment, including intermediate or
unfavorable cytogenetics in the majority of patients. Median age for patients
in the trial was 74 years. The trial includes three dosing schedules: Schedule
A, once weekly for three weeks (n=29); Schedule B, once weekly for two weeks
(n=35); and Schedule C, on days one and four at either 72 mg/m2 (n=29) or 90
mg/m2 (n=20).
* Median survival was
8.7 months in Schedule A; 5.8 months in Schedule B; and 7.3 months
(preliminary) in Schedule C (72 mg/m2 on days one and four).
* Median duration of
remission was 10.7 months and one year survival was 38% for Schedule A. For the
other schedules, median duration of remission has not been reached and one year
survival is too early to evaluate.
* Patients age 75 or
older (N=49) with at least 1 additional risk factor at diagnosis, a population
identified by the National Comprehensive Cancer Network (2010) AML Guidelines
as having poor outcome to standard treatment, experienced a CR rate of 30% and
a 30-day all-cause mortality of 5%. Survival in these patients was too early to
evaluate.
* Based on trial
results, Schedule C has been determined to be the recommended pivotal dose
regimen. For Schedule C, response rates (CR and CRp) are 38%; 30- and 60-day
all-cause mortality are 7% and 17% with improved tolerability over Schedule A.
"Voreloxin has
demonstrated a unique combination of anti-leukemic activity and tolerability,
important for patients who are unlikely to benefit from standard induction
therapy," said Robert K. Stuart, M.D., Professor of Medicine, Division of
Hematology/Oncology, Department of Medicine, Medical University of South
Carolina, and an investigator in the Phase 2 clinical trial. "Particularly
encouraging are the durable response, tolerability and promising survival
results in the Schedule C group. I look forward to seeing further data from
this trial as it matures, particularly voreloxin's durability and overall
survival in Schedule C."
Conference Call and
Slide Presentation Information
The company will host
a conference call and webcast slide presentation December 8, 2009 at 2:00 PM
EST to discuss the Company's new clinical data. Robert K. Stuart, M.D.,
Professor of Medicine, Division of Hematology/Oncology, Department of Medicine,
Medical University of South Carolina, will join the Sunesis senior management team
to review the updated data from the Company's Phase 2 studies of voreloxin. The
call can be accessed by dialing 888-726-2443 (U.S.
and Canada)
or 913-312-1516 (international). To access the live audio webcast and
accompanying slide presentation, or the subsequent archived recording, visit
the "Investors and Media - Calendar of Events" section of the Sunesis
website at www.sunesis.com. The webcast will be recorded and available for
replay on the company's website until December 22, 2009.
ABOUT VORELOXIN
Voreloxin is a
first-in-class anticancer quinolone derivative, or AQD, a class of compounds
that has not been used previously for the treatment of cancer. Voreloxin both
intercalates DNA and inhibits topoisomerase II, resulting in
replication-dependent, site-selective DNA damage, G2 arrest and apoptosis.
Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as
the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase
1b/2 clinical trial combining voreloxin with cytarabine for the treatment of
patients with relapsed/refractory AML, as well as in an ongoing Phase 2
single-agent trial in platinum-resistant ovarian cancer.
ABOUT ACUTE MYELOID
LEUKEMIA
AML is a rapidly
progressing cancer of the blood characterized by the uncontrolled proliferation
of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society
estimates that nearly 13,000 new cases of AML will be diagnosed and
approximately 9,000 deaths from AML will occur in the U.S. in 2009.
AML is generally a disease of older adults, and the median age of a patient
diagnosed with AML is about 67 years. AML patients with relapsed or refractory
disease and newly diagnosed AML patients over 60 years of age with poor
prognostic risk factors typically die within one year, resulting in an acute
need for new treatment options for these patients.
JAYHAWK ENERGY
INCORPORATED (OTCBB: JYHW)
"Up 18.57% in
morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/JYHW.php
JayHawk Energy, Inc.,
a development stage company, engages in the exploration, acquisition,
development, production, and sale of natural gas, crude oil, and natural gas
liquids primarily from conventional reservoirs in North
America. It owns interest in the Uniontown project covering 35,000
gross acres of non-producing coal bed methane natural gas reserves located in Bourbon County, Kansas.
The company was founded in 2004 as Bella Trading Company, Inc. and changed its
name to JayHawk Energy, Inc. in June 2007. JayHawk Energy, Inc. is based in Broomfield, Colorado.
JYHW News:
September 21 -
JayHawk Announces Discovery of Proven & Dependable Production Capabilities
and Extension of $800,000 Debenture
JayHawk Energy, Inc.
(OTCBB: JYHW) (“JayHawk”) provides an operational update regarding its
Southeast Kansas oil and gas projects namely the: (1) Uniontown project,
located in Bourbon County, Kansas; (2) Girard project, Crawford County, Kansas;
and (3) several other shallow oil opportunities within our existing acreage
that can exploited via Enhanced Oil Recovery (EOR) (collectively the
“Projects”). JayHawk previously entered into a joint venture with DK True
Energy Development Limited (“True Energy”) and its affiliates whereby True Energy
is to be the operator and will earn up to an 85% equity position in the
Projects via an investment of $1.8 MM over a 3 year period.
ABOUT THE UNIONTOWN
AND GIRARD PROJECTS
The Uniontown and
Girard projects consist of mineral leases covering approximately 45,000 gross
acres in Bourbon and Crawford Counties, Kansas within the mature Cherokee Basin.
The current target for development within those projects is the shallow gas
(75-300 m) potential of the area, although the leases are also held for
potential future development of coal-bed methane (“CBM”) and conventional oil
and gas resources. A preliminary resource estimate for these projects has been
prepared by Questa Engineering Corporation of Golden, Colorado and is available on the JayHawk
Energy website www.jayhawkenergy.com. There are in excess of 70 wells available
for recompletion. With the current low gas price only 5 wells are currently
producing with stabilized production being in excess of 105 mcf/day. True
Energy has piloted 5 wells with its proprietary technologies including the
Short Radius Stimulation (SRS) and the Gas Gun (modified propellant gun
technology) in order to demonstrate its low cost completion & stimulation
techniques (below $10,000 USD per well). It is expected that as natural gas prices
firm up, the respective CBM wells can be rapidly brought on line both
expeditiously and economically with additional drilling ensuing.
Shallow Oil Resources
Concurrent to
completing its geological and reservoir due diligence on the “Home Run” Kansas
CBM project, True Energy has further delineated significant oil reservoirs that
have been over-looked or were prematurely shut-in during the 1980s and now
provide an opportunity to restart that project as much of the infrastructure is
in place.
The Home Run project
areas are located on the Missouri side of the
prolific Cherokee
Basin, known for shallow
oil saturated sandstones. For optimum recovery the projects require
waterflooding with additional chemical flooding in order to both drive the
hydrocarbons from the reservoir into the production well bore and to reduce the
residual oil within the reservoir. The water chemical mixture is introduced by
a number of injector wells drilled within the project area on a “five spot
pattern” with four production wells for each injector well.
The eastern side of
the Cherokee Basin is estimated to contain between
1.8 and 8 billion barrels of oil in place based on published reports from the
United States Geological Survey (“USGS”) and Missouri Department of Natural Resources
Survey.
Following its
analysis of the region, True Energy now has an increased understanding of the
characteristics of the project acreage and has demonstrated there are several
reservoirs present. All of the reservoirs discovered target the Upper and Lower Bartlesville formations and which possess excellent
porosity and permeability with an API oil gravity ranging from 28 to 33. True
Energy will be working to confirm the placement and rollout of several
waterflood commercial pilots in the area.
JayHawk CEO Lindsay
Gorrill states “we are extremely pleased by this outcome, these developments
provide a significant increase in the resource base of JayHawk that was not
expected during our initial due diligence phase in Kansas. This has provided the company the
ability to take advantage of both rising oil and gas prices, while staying
within our stated goals of acquiring low cost, near term production
opportunities in the US
oil and gas market.”
The company has also
successfully negotiated the extension, to July 31, 2010, a $800,000 debenture
payable to Starshell Consultants.
BIOTIME INCORPORATED
(OTCBB: BTIM)
"Up 19.86% in
morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BTIM.php
BioTime,
headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. BioTime
develops and markets research products in the field of stem cells and
regenerative medicine through its wholly owned subsidiary Embryome Sciences,
Inc. BioTime’s subsidiary OncoCyte Corporation focuses on the therapeutic
applications of stem cell technology in cancer. BioTime also plans to develop
therapeutic products in China
for the treatment of ophthalmologic, skin, musculo-skeletal system and
hematologic diseases, including the targeting of genetically modified stem
cells to tumors as a novel means of treating currently incurable forms of
cancer through its subsidiary BioTime Asia. In addition to its stem cell
products, BioTime markets blood plasma volume expanders and related technology
for use in surgery, emergency trauma treatment, and other applications.
BioTime's lead product, Hextend®, is a blood plasma volume expander
manufactured and distributed in the U.S.
by Hospira, Inc. and in South
Korea by CJ CheilJedang Corp. under
exclusive licensing agreements.
BTIM News:
December 4 - BioTime
CEO Dr. Michael West to Ring The Opening Bell at the New York Stock Exchange
BioTime, Inc. (NYSE
Amex: BTIM) Chief Executive Officer Michael D. West, Ph.D. will ring The
Opening Bell at the New York Stock Exchange at 9:30 a.m. Eastern on Tuesday,
December 8, 2009. Executives and guests of BioTime will also be at the ceremony
to celebrate the company's recent listing on the NYSE Amex. Trading of
BioTime’s common shares and warrants commenced on the NYSE Amex on Friday,
October 30, 2009 under the ticker symbols “BTIM” for the common shares and
“BTIM.WS” for the warrants.
The bell ringing will
be webcast live on www.nyse.com and live to the jumbo screen on the W Hotel in Times Square. Both live and archive links for the bell
ringing will also be posted on BioTime’s website at www.biotimeinc.com.
RMD ENTERTAINMENT
GROUP (OTC: RMDM)
"Up 20.00% in
morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/RMDM.php
RMD Entertainment
Group, an entertainment company, primarily focuses on the development and
marketing of hip-hop music in the United States and internationally.
It develops and markets hip-hop music, including compact discs, digital
downloads, and personal ring tones for mobile phone customers, as well as other
hip-hop lifestyle products. The company has also created MOTV, which streams
video content to mobile devices, including cell phones and PDAs. It markets its
products primarily through distributors. RMD Entertainment Group is based in Philadelphia, Pennsylvania.
RMDM News:
December 8 - United
Liquor Alliance
Seeks Strategic Partnership and Vendor Relationship Green World Path, Inc.
RMD Entertainment's
(OTC: RMDM) subsidiary United Liquor Alliance (www.united-liquor.com) seeks
strategic partnership and vendor relationship Green World Path, Inc.
Green World Path has
focused the past 35 years promoting a new kind of sustainable agriculture in
which mankind and the environment are as important as profits. The result has
been the development of a unique line of products that combine ingredients like
botanicals, ocean-harvested fish and sea plants, fermented complex sugars,
organic carbons, clean offal, bacteria, enzymes, and minerals with special
chelators and catalysts (utilizing the latest in biotechnology). These advanced
formulations offer dramatic examples of adding value to natural raw materials,
which become high-tech agricultural products commanding premium prices. Green
World Path, Inc. manufactures over 45 innovative products for sustainable
agriculture and other green industries.
ULA talks with Green
World Path centered around 3 major issues focusing on continued growth.
The first is the
byproduct created by the use of molasses. ULA uses molasses in the production
of rum, what is left is a thick syrup which most companies traditionally pay to
dispose of. ULA plans to turn the by-product into a profit center verses an
added expense. Green World Path would be able to utilize the by-product to
create environmentally friendly products.
The second issue
discussed was the use of herbal healthy remedies which help alleviate the side
effects associated with hangovers. ULA plans to market a follow up to the
bottle water with a natural hangover solution which can be bottled with water
and sold at high margins with the same distributors for alcohol.
The third issue
discussed was utilizing environmentally safe containers. "The containers
we utilize for our products are one of the largest expenses. We want to work
with companies like Green World Path to not only find lower costing products
but more environmentally safe" said Shane Cooper of ULA.
PLATEAU MINERAL
DEVELOPMENT INCORPORATED (OTC: PMDP)
"Up 11.11% in
morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/PMDP.php
Plateau Mineral
Development, Inc. specializes in the exploration and development of energy
sources. Its partner, Plateau Mineral Development LLC, has been in existence
for over five years with successful new wells and rework wells selling both gas
and oil.
PMDP News:
December 8 - Plateau
Mineral Development, Inc. Announces Appointment of William Strange as President
Plateau Mineral
Development, Inc. (OTC: PMDP), along with its partner, Plateau Mineral
Development LLC, announced today that the company has appointed William Strange
as President, effective immediately.
William
"Bill" Strange has thirty years of experience in the refineries,
petro-chemical, and oil field. He is well-versed in bio-remediation,
pipefitting and fabrication, process troubleshooting and construction
management. Mr. Strange was employed for more than ten years by Raines
Contractors in Galena Park,
Texas, where he served as
construction manager and marketing director, whilst heading the bio-remediation
department. He supervised daily operations, implemented safety programs,
initiated business development projects, and took part in contract
negotiations. Principally, he acted as chief negotiator between the company and
Chevron. Presently, Mr. Strange acts as a consultant for Jarrell Welding and
Fabrication where he assists with new business opportunities, participates in
construction contract negotiations, and troubleshoots jobs.
William Strange,
President elect for Plateau, states, "I am honored to have been chosen for
this position and am eager to get started. I believe that a great deal of
potential lies within Plateau, and I'm looking forward to taking part in the
growth of the company."
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper,
TX 75078,
Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This
email address is being protected from spam bots, you need Javascript enabled to
view it.
DO NOT BASE ANY
INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not
registered as a securities broker-dealer or an investment adviser either with
the U.S. Securities and Exchange Commission (the "SEC") or with any
state securities regulatory authority. We are neither licensed nor qualified to
provide investment advice. OTCPicks.com makes no recommendation that the
purchase of securities of companies profiled in this web site is suitable or
advisable for any person or that an investment such securities will be
profitable. In general, given the nature of the companies profiled and the lack
of an active trading market for their securities, investing in such securities
is highly speculative and carries a high degree of risk. You are receiving this
email because you have registered on OTCPicks.com or one of our affiliate
companies.
The information
contained in our report should be viewed as commercial advertisement and is not
intended to be investment advice. The report is not provided to any particular
individual with a view toward their individual circumstances. The information
contained in our report is not an offer to buy or sell securities. We
distribute opinions, comments and information free of charge exclusively to
individuals who wish to receive them.
Our newsletter and
website have been prepared for informational purposes only and are not intended
to be used as a complete source of information on any particular company. An
individual should never invest in the securities of any company profiled based
solely on information contained in our reports. Individuals should assume that
all information contained in the report about profiled companies is not
trustworthy unless verified by their own independent research.
Any individual who
chooses to invest in any securities should do so with caution. Investing in
securities is speculative and carries a high degree of risk; you may lose some
or all of the money that is invested. Always research your own investments and
consult with a registered investment advisor or licensed stock broker before
investing.
Information contained
in our report will contain "forward looking statements" as defined
under Section 27A of the Securities Act of 1933 and Section 21B of the
Securities Exchange Act of 1934. Subscribers are cautioned not to place undue
reliance upon these forward looking statements. These forward looking
statements are subject to a number of known and unknown risks and uncertainties
outside of our control that could cause actual operations or results to differ
materially from those anticipated. Factors that could affect performance
include, but are not limited to, those factors that are discussed in each
profiled company's most recent reports or registration statements filed with
the SEC. You should consider these factors in evaluating the forward looking
statements included in the report and not place undue reliance upon such
statements. We are committed to providing factual information on the companies
that are profiled. However, we do not provide any assurance as to the accuracy
or completeness of the information provided, including information regarding a
profiled company's plans or ability to effect any planned or proposed actions.
We have no first-hand knowledge of any profiled company's operations and
therefore cannot comment on their capabilities, intent, resources, nor
experience and we make no attempt to do so. Statistical information, dollar
amounts, and market size data was provided by the subject company and related
public information sources which we believe to be reliable but we cannot
guarantee the accuracy of the information. To the fullest extent of the law, we
will not be liable to any person or entity for the quality, accuracy,
completeness, reliability, or timeliness of the information provided in the
report, or for any direct, indirect, consequential, incidental, special or punitive
damages that may arise out of the use of information we provide to any person
or entity (including, but not limited to, lost profits, loss of opportunities,
trading losses, and damages that may result from any inaccuracy or
incompleteness of this information). We encourage you to invest carefully and
read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure:
OTCPicks.com has received three thousand dollars from a third party (Heritage
First Capital) for LUXE advertising and promotional services. OTCPicks.com has
been compensated two thousand dollars by a third party (Blue Wave Advisors) for
a one week GTWO advertising and promotional program. OTCPicks.com has been
compensated ten thousand dollars by a third party (Emerging Market Consultants)
for GTWO advertising and promotional services. OTCPicks.com has been
compensated four thousand dollars by a third party for a one-week GELV
advertising and promotional program. OTCPicks.com has been previously
compensated seven thousand five hundred dollars by a third party for BMGP
advertising and promotional services. OTCPicks.com has been compensated twelve
thousand five hundred dollars by a third party for BMGP advertising and
promotional services. OTCPicks has been compensated two thousand five hundred
dollars from a non-controlling third party (BlueWave Advisors) for WWPW
advertising and promotional services. This compensation constitutes a conflict
of interest as to our ability to remain objective in our communication
regarding the profiled company. OTCPicks.com is a website partially owned by
BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors,
LLC, its principal and/or its affiliates will hold positions in the company
profiled and may buy or sell securities at any time without notice.
